MARKET

DFFN

DFFN

Diffusion Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4405
-0.0035
-0.79%
Opening 10:20 01/28 EST
OPEN
0.4416
PREV CLOSE
0.4440
HIGH
0.4500
LOW
0.4400
VOLUME
269.90K
TURNOVER
--
52 WEEK HIGH
11.00
52 WEEK LOW
0.2110
MARKET CAP
14.72M
P/E (TTM)
-0.1208
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of DFFN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

DFFN News

  • Diffusion Pharmaceuticals Appoints Life Sciences Veteran Dr. Robert Cobuzzi, Jr. to its Board of Directors
  • GlobeNewswire.01/10 13:00
  • DFFN: Highly Encouraging Data from Run-in Portion of Phase 3 GBM Trial…
  • Zacks Small Cap Research.12/30/2019 13:00
  • Hedge Funds Have Never Been More Bullish On Diffusion Pharmaceuticals Inc. (DFFN)
  • Insider Monkey.12/22/2019 23:43
  • 10 Biggest Price Target Changes For Wednesday
  • Benzinga.12/18/2019 13:39

More

Industry

Biotechnology & Medical Research
+1.23%
Pharmaceuticals & Medical Research
+0.59%

Hot Stocks

Name
Price
%Change

About DFFN

Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company's Diffusion's technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.
More

Webull offers Diffusion Pharmaceuticals Inc (DFFN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.